Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients

Launched by AIN SHAMS UNIVERSITY · Apr 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well a substance called Interleukin-6 (IL-6) works compared to another substance called procalcitonin in identifying sepsis in burn patients. Sepsis is a serious condition that can occur when an infection spreads throughout the body, especially in patients who have suffered burns. The researchers want to find out if measuring IL-6 levels can help doctors know more quickly if a treatment is working and if patients can be safely discharged from the intensive care unit (ICU) sooner.

To participate in this trial, patients must be admitted to the burn ICU within 24 hours of their injury and have burns covering 25% to 50% of their body. Only second to third-degree burns will qualify, and patients should be in good health before the burn (classified as ASA 1 or ASA 2, which means they have minimal or no health issues). Patients with burns on more than 50% of their body, those with autoimmune diseases, or those with cancer are not eligible for this study. Participants will undergo tests to measure their IL-6 and procalcitonin levels and will be closely monitored during their treatment in the ICU.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
• • patients with burn percentage of 25% to 50% of total body surface area
• • patients with second to third degree burns
• • ASA 1 and ASA 2 patients
• Exclusion Criteria:
• • Burn percentage more than 50% or less than 25% of total body surface area
• • Having autoimmune diseases
• • Cancer patients
• • ASA 3 and ASA 4 patients